700832-92-4

Upstream product

• 865236-23-3 3-{4-[1-ethyl-1-(4-hydroxy-3-methyl-phenyl)-propyl]-2-methyl-phenyl}-propionic acid methyl ester 
• 594-19-4 tert.-butyl lithium 
• 700832-91-3 3'-[4-(3-oxo-4,4-dimethylphenyl)-3-methylphenyl]-3'-[4-benzyloxy-3-methylphenyl]pentane 

Downstream Products

• 700832-93-5 trifluoro-methanesulfonic acid 4-{1-[4-(4,4-dimethyl-3-oxo-pentyl)-3-methyl-phenyl]-1-ethyl-propyl}-2-methyl-phenyl ester 
• 865236-21-1 4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]-propyl}-2-methylphenol 

Relevant academic research and scientific papers

Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators

The present invention relates to a method of treating or preventing damage to human skin cells by chemical vesicants by administering a non-secosteroidal, diphenyl compound with vitamin D receptor (VDR) modulating activity.

BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS

The present invention discloses bisphenyl compounds of the formula (I): wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals.

VITAMIN D RECEPTOR MODULATORS

The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.